Iradimed's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Iradimed (IRMD) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Iradimed vs Its Competitors
- TTM: Trailing 12-month revenue of 86M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is decelerating (-5.2% annualized vs trailing 12 months).
- Scale: Iradimed ranks #66 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.1% of industry market cap.
- Peer revenue share: Iradimed accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
IRMD Sales vs. its Competitors, Q2 2026
Iradimed generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Medical Equipment & Supplies industry grew revenue 15.0% year over year, combined, vs 0.3% for Iradimed. Iradimed's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Iradimed's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Iradimed Corporation | Yes | Yes | Yes | Yes |
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 62.50 % (5 of 8) | 25.00 % (2 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
IRMD Stock Performance relative to its Competitors
IRMD Stock Performance relative to Similar-Size Competitors
IRMD Stock Performance relative to Similar Growth & Profitability Competitors
Iradimed's Comment on Competition and Industry Peers
Iradimed's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| MIPM Mammendorfer Institut für Physik und Medizin | Named by the company | 85% |
| Fresenius Kabi | Named by the company | 85% |
| B. Braun | Named by the company | 85% |
| MEDRAD, Inc. | Named by the company | 85% |
| Bayer Radiology | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Iradimed's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.